Amgen (radiation syndrome)
Thousand Oaks, CA, United StatesFounded 1980Industry
Amgen's Nplate is FDA-approved for hematopoietic acute radiation syndrome, and BARDA has bought more doses and funded an administration kit for it.
What it does
Threats covered
Categories
Profile
Amgen is a Thousand Oaks, California biopharmaceutical company listed on Nasdaq under AMGN. On 28 January 2021 the US Food and Drug Administration approved its Nplate (romiplostim) to increase survival in adults and children, including term neonates, who have been acutely exposed to myelosuppressive doses of radiation, a condition called haematopoietic syndrome of acute radiation syndrome.
More profile
The approved dose is 10 micrograms per kilogram, given once by subcutaneous injection as soon as possible after suspected or confirmed exposure above 2 gray. Approval was granted under the Animal Rule because human efficacy studies are not ethical or feasible, and the FDA required a postmarketing observational study.
Nplate is mainly sold for immune thrombocytopenia, so this is one indication of a very large commercial product.
Ownership
Publicly listed on Nasdaq (AMGN)
Parent: none (publicly listed) (checked)
Sources (5)
- https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=639818
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125268s167lbl.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/125268Orig1s167ltr.pdf
- https://content.govdelivery.com/accounts/USFDA/bulletins/2bd82f3
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125268s168lbl.pdf
Not verified or not found
- Founding year 1980 and the Nasdaq listing: not shown in these sources.
- Government procurement of Nplate for stockpiles: not read.
Questions
What does Amgen (radiation syndrome) do?
Amgen's Nplate is FDA-approved for hematopoietic acute radiation syndrome, and BARDA has bought more doses and funded an administration kit for it.
Where is Amgen (radiation syndrome) based?
HQ (as found): Thousand Oaks, CA. HQ country: US.
Who owns Amgen (radiation syndrome)?
Publicly listed on Nasdaq (AMGN). Parent: none (publicly listed) (checked)
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction